Mild cognitive impairment (MCI) causes a slight but measurable decline in cognitive abilities, including memory and thinking skills, but does not affect the individual’s ability to carry out everyday activities. In many cases, MCI represents a transitional state between normal ageing and Alzheimer’s disease, and is characterised by a cognitive decline that is greater than expected based on a person’s age. Up to 890,000 people suffer from MCI in Australia and New Zealand alone, and this number is set to grow as the population ages. Typically, people do not know that they have MCI until it is too late and has progressed to Alzheimer’s disease.
Danone Nutricia Research is looking for an affordable and scalable technological solution that can help screen for MCI in older adults, and potentially connect these older adults to healthcare professionals, for example, General Practitioners familiar with MCI or specialist physicians such as geriatricians, neurologists or psychogeriatricians.
Submit your proposal here.
We would like to avoid expensive and cumbersome devices.